CEO Resigns Amidst Going Concern & Delisting Threat; CFO Appointed Interim CEO

summarizeSummary

Cue Biopharma announced the resignation of its President and CEO, Usman Azam, amidst severe financial distress and delisting threats, appointing CFO Lucinda Warren as Interim CEO.

check_boxKey Events

• CEO Resignation

  Usman Azam resigned as President and Chief Executive Officer and as a member of the Board, effective March 26, 2026. This follows the company's recent 10-K filing on March 16, 2026, which disclosed substantial doubt about its ability to continue as a going concern and an active Nasdaq delisting threat.

• Interim CEO Appointment

  Lucinda Warren, the current Chief Financial and Business Officer, was appointed Interim President and Chief Executive Officer, effective March 27, 2026. She will continue to serve in her CFO and Business Officer roles.

• Interim CEO Compensation Package

  Ms. Warren's amended employment agreement includes an annual base salary of $525,000, a $10,000 monthly supplement as Interim CEO, a target discretionary incentive bonus of up to 45% of her base salary, and a stock option grant for approximately 1.0% of the company's outstanding shares upon achievement of a specified financing milestone.

• Former CEO Severance Terms

  Dr. Azam will receive a lump sum cash severance payment of $232,500 and continued payment of COBRA health insurance premiums for 12 months, subject to certain conditions.

auto_awesomeAnalysis

This 8-K filing signals significant leadership instability at a critical juncture for Cue Biopharma. The departure of CEO Usman Azam comes just days after the company disclosed substantial doubt about its ability to continue as a going concern and an active Nasdaq delisting threat in its 10-K. While the appointment of current CFO Lucinda Warren as Interim CEO provides some continuity, the 'interim' nature of the role, coupled with her dual responsibilities, may raise questions about long-term strategic direction. The substantial compensation package for the interim CEO, including a stock option representing 1.0% of outstanding shares, is notable for a company facing such severe financial challenges and potential dilution from recent shelf and ATM filings. Investors should view this as a further negative development, exacerbating concerns about the company's ability to navigate its current crisis.